01
Sep
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations, Business News
Business new tamfitronics Guardant360® CDxis the first blood-based companion diagnostic to be approved...